Stock listing

07X Stock Price, News, Filings & Events — Annovis Bio, Inc.

Selected listing: 07X · GETTEX · EUR · DE

This page tracks Annovis Bio, Inc.'s 07X:GETTEX listing on GETTEX in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following 07X:GETTEX. 07X:GETTEX is the stock-level entry point for investors researching Annovis Bio, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Annovis Bio, Inc. (ticker: ANVS) is a public company based in America, with a market capitalization of approximately $70.6 million. The company focuses on developing therapies for neurodegenerative diseases. Annovis Bio aims to address significant unmet medical needs through its innovative research and development efforts.

07X:GETTEXEURDEUpdated August 21, 2026
Annovis Bio, Inc. logo
Ticker
07X:GETTEX
Asset type
Stock
Market cap
$77.5M
Sector
Health Technology
Industry
Pharmaceuticals: Major
Exchange
GETTEX
Currency
EUR

Annovis Bio, Inc. 07X:GETTEX stock context

This page tracks Annovis Bio, Inc.'s 07X:GETTEX listing on GETTEX in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following 07X:GETTEX. 07X:GETTEX is the stock-level entry point for investors researching Annovis Bio, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Annovis Bio, Inc. (ticker: ANVS) is a public company based in America, with a market capitalization of approximately $70.6 million. The company focuses on developing therapies for neurodegenerative diseases. Annovis Bio aims to address significant unmet medical needs through its innovative research and development efforts.

Latest news from Annovis Bio, Inc.

All Annovis Bio, Inc. news →

Research Annovis Bio, Inc.

Alternate listings